Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injuryDesign includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 daysVYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants